Paving the way for future PSMA inhibitors: insights from comparative preclinical evaluations of structure modifications

Abstract Background Prostate-specific membrane antigen (PSMA) is an established target for the imaging and treatment of prostate cancer. This study focused on the preclinical evaluation of three novel PSMA inhibitors—P15, P16, and P19—which were structurally modified compared to the clinically used...

Full description

Bibliographic Details

Published in:	EJNMMI Radiopharmacy and Chemistry
Main Authors:	Katarína Hajduová, Kateřina Dvořáková Bendová, Miloš Petřík, Martina Benešová-Schäfer, Martin Schäfer, Marián Hajdúch, Zbyněk Nový
Format:	Article
Language:	English
Published:	SpringerOpen 2025-09-01
Subjects:	PSMA Prostate cancer Preclicnical PET/CT Theranostics Radiopharmaceuticals
Online Access:	https://doi.org/10.1186/s41181-025-00389-w